Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: Results Through 24 Months From a Phase 1 Study (S37.005)
To report the safety of bemdaneprocel and its impact on clinical outcomes in participants with PD through 24 months post transplantation.
Authors
- Kenny Kwok Hei Yu (ORCID: https://orcid.org/0000-0002-2394-4990)
- Suneil K. Kalia (ORCID: https://orcid.org/0000-0003-2054-1915)
- Harini Sarva (ORCID: https://orcid.org/0000-0002-0320-2893)
- Alfonso A. Fasano (ORCID: https://orcid.org/0000-0001-5346-0180)
- Andrés M. Lozano (ORCID: https://orcid.org/0000-0001-8257-3694)
- Viviane Tabar (ORCID: https://orcid.org/0000-0002-1284-1670)
- Claire Henchcliffe (ORCID: https://orcid.org/0000-0002-0899-3030)
- Cameron Brennan (ORCID: https://orcid.org/0000-0003-4064-8891)
- Whitney Stemple
- Nicole Floro
- Nauman Abid
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- University of Toronto (CA)
- University of California, Irvine (US)
- Cornell University (US)
- Toronto Western Hospital (CA)
- Ontario Brain Institute (CA)
- Weill Cornell Medicine (US)
- Krembil Brain Institute
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208808
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00